Sokolski Kenneth N
Department of Psychiatry, University of California, Irvine, CA, USA.
Ann Pharmacother. 2007 Jan;41(1):35-40. doi: 10.1345/aph.1H294. Epub 2006 Dec 26.
Aripiprazole has demonstrated efficacy in treatment of bipolar mania, as well as in the maintenance treatment of bipolar disorder. There has been only one report supporting a role for this agent in the depressed phase of the illness.
To evaluate the effectiveness of adjunctive aripiprazole in bipolar I depressed patients who are nonresponders to standard therapy.
Chart records were reviewed for all patients with bipolar I depression, diagnosed by Diagnostic and Statistical Manual of Mental Disorders, 4th revision, criteria between June 2004 and January 2006 from the Long Beach Veterans Affairs Mood Disorders Clinic. Included subjects had experienced moderate to marked depressive symptoms (Clinical Global Impression-Bipolar Depression > or =4) despite at least 2 months of treatment with adequate doses of at least one mood stabilizer. In addition, all subjects had been treated subsequently with aripiprazole 15-30 mg/day added to the existing regimen. Detailed chart notes were used to retrospectively rate symptoms. The presence or absence of each symptom was recorded before and after aripiprazole augmentation. Based on these data, Clinical Global Impression bipolar severity (CGI-BP-S) ratings and CGI-BP improvement scores for bipolar I depression were assigned.
Ten subjects met study criteria. Adjunctive aripiprazole given for 21-110 days resulted in significant improvements in CGI-BP-S depression ratings. Seven of 10 patients were assigned CGI-BP improvement ratings of much or very much improved. Adverse events were mild and included akathisia, nausea, and insomnia. Dose adjustments of aripiprazole or the addition of drugs to treat adverse effects excluded subjects from further data collection. No patient stopped aripiprazole due to adverse effects.
This study adds to a previous report indicating beneficial effects of adjunctive aripiprazole in treatment of bipolar I depression. Double-blind, placebo-controlled investigations are needed to confirm these findings.
阿立哌唑已被证明在治疗双相躁狂症以及双相情感障碍的维持治疗中有效。仅有一份报告支持该药物在疾病抑郁期的作用。
评估辅助使用阿立哌唑对标准治疗无反应的双相I型抑郁症患者的有效性。
回顾了2004年6月至2006年1月期间长滩退伍军人事务部情绪障碍诊所根据《精神疾病诊断与统计手册》第4版标准诊断的所有双相I型抑郁症患者的病历记录。纳入的受试者尽管使用至少一种心境稳定剂足量治疗至少2个月,但仍有中度至重度抑郁症状(临床总体印象-双相抑郁>或=4)。此外,所有受试者随后在现有治疗方案基础上加用阿立哌唑15-30mg/天进行治疗。使用详细的病历记录进行症状回顾性评分。在阿立哌唑增效治疗前后记录每种症状的有无。基于这些数据,给出双相I型抑郁症的临床总体印象双相严重程度(CGI-BP-S)评分和CGI-BP改善分数。
10名受试者符合研究标准。辅助使用阿立哌唑21-110天导致CGI-BP-S抑郁评分显著改善。10名患者中有7名被评定为CGI-BP改善程度为明显或非常明显改善。不良事件轻微,包括静坐不能、恶心和失眠。阿立哌唑剂量调整或加用药物治疗不良反应使受试者被排除在进一步的数据收集之外。没有患者因不良反应而停用阿立哌唑。
本研究补充了先前的一份报告,表明辅助使用阿立哌唑对双相I型抑郁症治疗有有益作用。需要进行双盲、安慰剂对照研究来证实这些发现。